Slingshot members are tracking this event:
Onconova Therapeutics, Inc. Receives Notice of Termination for Convenience from Baxalta for rigosertib
Do you think this event is important to the companies below? How will it affect their stock price?
Until the August 30, 2016 termination date, Baxalta is obligated to provide various financial contributions, including 50 percent of the clinical trial costs for the INSPIRE trial up to a specified cap. Onconova is currently in discussions with Baxalta regarding the amount of financial support sufficient to complete the INSPIRE trial that was commenced in December following consultation with Baxalta.
Slingshot Insights Explained
Mar 03, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Notice Of Termination, Cancer, Rigosertib, Inspire Trial, Intravenous, Higher-risk Myelodysplastic Syndromes, Hr-mds, Hma, Hypomethylating Agent Therapy